Published in J Clin Oncol on April 15, 2001
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol (2013) 1.89
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr (2004) 1.45
Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. Br J Cancer (2010) 1.37
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One (2007) 1.29
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res (2003) 1.21
p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res (2006) 1.03
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res (2014) 1.01
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol (2009) 1.01
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer (2005) 0.95
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer (2010) 0.88
Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. Breast Cancer Res (2001) 0.86
HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics (2011) 0.83
Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer (2004) 0.83
Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care (2012) 0.82
Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. Onco Targets Ther (2014) 0.80
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int (2014) 0.78
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol (2010) 0.76
Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. Nutr Metab (Lond) (2010) 0.76
The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance. Drug Des Devel Ther (2015) 0.76
HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies. J Korean Med Sci (2004) 0.76
Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer. Onco Targets Ther (2015) 0.75
Protocol for HER2 FISH determination on PAXgene-fixed and paraffin-embedded tissue in breast cancer. Int J Exp Pathol (2016) 0.75
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open (2016) 0.75
Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol (2005) 0.75
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer (2006) 2.14
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol (2007) 2.05
Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia (2001) 2.02
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94
New prognostic factors for breast cancer recurrence. Semin Oncol (2001) 1.77
Early endoscopy. A guide to therapy for acute hemorrhage in the upper gastrointestinal tract. Arch Surg (1973) 1.77
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol (1998) 1.59
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol (1988) 1.43
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39
We may be lost, but we're sure makin' good time. Cancer Invest (1993) 1.38
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27
Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res (1992) 1.14
Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol (1998) 1.09
Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol (1995) 1.07
Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun (1989) 1.05
Healing flare in skeletal metastases from breast cancer. Radiology (1994) 1.05
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol (1997) 1.04
New agents and new medical treatments for advanced breast cancer. Semin Oncol (1987) 1.04
Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res (1986) 1.03
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol (2008) 1.02
Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med (1996) 1.01
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00
Modeling hot flushes and quality of life in breast cancer survivors. Climacteric (2010) 1.00
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer (2010) 0.99
Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat (2003) 0.98
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol (1985) 0.97
Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer (1990) 0.96
Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat (1999) 0.96
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat (2011) 0.93
Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol (2013) 0.93
Adjuvant therapy for all patients with breast cancer? J Natl Cancer Inst (2001) 0.93
Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst (2000) 0.93
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol (2004) 0.90
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer (2009) 0.88
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol (2001) 0.88
Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat (1998) 0.87
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. Br J Cancer (2013) 0.87
CAF in metastatic breast cancer: standard therapy or another effective regimen? J Clin Oncol (1987) 0.86
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat (1999) 0.86
Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys (1999) 0.86
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther (2010) 0.83
Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol (2000) 0.83
Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res (2001) 0.83
Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res (1992) 0.83
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol (1999) 0.82
Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon. Cancer (1993) 0.81
The quantitation of carbamino adduct formation of angiotensin II and bradykinin. Biophys J (1978) 0.81
Adjuvant systemic therapy for patients with node-negative tumors. Cancer (1990) 0.81
Circulating tumor markers in breast cancer. Hematol Oncol Clin North Am (1989) 0.81
High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Oncology (Williston Park) (1997) 0.80
Implications for clinical management in patients with breast cancer. Long-term effects of reconstruction surgery. Cancer (1991) 0.80
Ductal carcinoma in situ of the breast: a new model. J Natl Cancer Inst (1997) 0.80
Comprehensive management of disseminated breast cancer. Cancer (1990) 0.79
Should we treat HER, too? J Clin Oncol (1996) 0.79
Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res (1990) 0.78
Detection and characterization of a high molecular weight human lung carcinoma-associated glycoprotein. Cancer Res (1990) 0.78
The Role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer (2001) 0.78
What would you do if this were your ... wife, sister, mother, self? J Clin Oncol (1991) 0.78
No evidence for MUC 1-induced apoptosis. Nat Med (1998) 0.77
Primary radiation therapy for locally advanced breast cancer. Cancer (1987) 0.77
The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck. J Surg Oncol (1986) 0.77
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst (1993) 0.77
Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. Clin Cancer Res (1995) 0.77
Renal vasoconstriction in association with acute pancreatitis. Am J Surg (1974) 0.77
Closure of an aortic stump. A new method. Am J Surg (1983) 0.76
Bilateral tube thoracostomy to preclude fatal tension pneumothorax in patients with acute respiratory insufficiency. Am Surg (1976) 0.76
Doxorubicin for inflammatory breast cancer: a red humor for a red tumor? Ann Surg Oncol (1995) 0.75
Clinical experience with carotid stump pressure and EEG monitoring to determine shunt placement during carotid endarterectomy. J Natl Med Assoc (1983) 0.75
Fine-needle aspiration and flow cytometry for evaluation of primary breast cancer. Radiology (1992) 0.75
A "breathalyser" for lung cancer? Lancet (1999) 0.75
Transvenous biopsy of carcinoma of bronchus causing superior vena caval obstruction. Br Med J (1975) 0.75
Psychosocial issues in breast reconstruction. Cancer (1991) 0.75
Current recommendations on breast cancer treatment. Contemp Intern Med (1993) 0.75
Axillary lymphoscintigraphy for breast cancer: should we do it? Can we do it? J Nucl Med (1990) 0.75
Lung cancer-associated protein: development and characterization of a new assay that detects a circulating lung cancer marker. Cancer Res (1991) 0.75